ILiAD Biotechnologies
New York · Founded 2012
About ILiAD Biotechnologies
ILiAD Biotechnologies (ILiAD) is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. ILiAD's lead candidate is BPZE1, a live-attenuated pertussis vaccine that has successfully completed a Phase 1 human clinical trial. ILiAD Biotechnologies is a registered Delaware company founded in 2012.
Company Facts
- Founded: 2012
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $180.0M
- Funding stage: Late Stage Venture
- Last round: Series D (Feb 2026)
- Website: http://iliadbio.com/
- Phone: +1 917-913-8511
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/iliad-biotechnologies-7614 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.